Please assess the completion status of the following clinical trial:

Trial Title: The Von Willebrand Disease (VWD) International Prophylaxis Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Type 1: eligible for participation if~* ≤20% RCo and/or ≤20% FVIII; and~* DDAVP non-responsive, defined as occurrence of bleeding episodes not responding satisfactorily to desmopressin, or deemed non-responsive a priori by the investigator; and~* Bleeding indication criteria are met~Type 2: eligible for participation if~* DDAVP non-responsive, defined as occurrence of bleeding episodes not responding satisfactorily to desmopressin, or deemed non-responsive a priori by the investigator; or Type 2B;~* Bleeding indication criteria are met~Type 3: eligible for participation if~* Bleeding indication criteria are met~Bleeding Indication Criteria:~* Joint Bleeding: documentation of at least two apparently spontaneous bleeding episodes in the same joint in the six months prior to enrollment; or three or more apparently spontaneous bleeding episodes in different joints in the six months prior to enrollment.~* GI Bleeding: history of two or more severe GI bleeding episodes associated with either a drop in hemoglobin of ≥ 2 g/dl or requiring red blood cell transfusion or treatment with VWD concentrate.~* Failure to identify other causes of bleeding.~* Menorrhagia: a diagnosis of menorrhagia; prospectively completed Pictorial Blood Assessment Chart score \>185 or required treatment with a VWD product for menstrual bleeding on one or more occasions in the year prior to enrollment.~* Normal cervical cytology (PAP) within the six months prior to enrollment for females ≥ 18 years of age.~* Epistaxis 1. Three or more bleeding episodes in a six-month period that required treatment with VWD concentrates or red cell transfusions.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VWF/FVIII product infusions (Type: None): One to three infusions of factor replacement as needed to control bleeding.

Based on this trial design, predict the completion outcome and termination type (if applicable).